Patent details

EN | LT

LT - Medical use of a therapeutic combination comprising a thymosin-1-alpha polypeptide and a replication competent retroviral vector for the expression of cytosine deaminase.

EN - Medical use of a therapeutic combination comprising a thymosin-1-alpha polypeptide and a replication competent retroviral vector for the expression of cytosine deaminase.

Legal status

Patent not validated

Bibliographic data

Indications of the International Patent Classification (IPC)
(51)	INT.CL.	A61K 38/16
		A61K 38/17
		A61K 38/22
		A61K 48/00
		C12N 15/86
		C12N 15/867
		A61P 35/00
		C12N 9/78

European patent
(11)	Number of the document	2547353
(13)	Kind of document	T
(96)	European patent application number	11766479.7
	Date of filing the European patent application	2011-03-29
(97)	Date of publication of the European application	2013-01-23
(45)	Date of publication and mention of the grant of the patent	2019-03-06
(46)	Date of publication of the claims translation

PCT application
(86)	Number	PCT/US2011/030402
	Date	2011-03-29

PCT application publication
(87)	Number	WO 2011/126864
	Date	2011-10-13

Priority applications
(30)	Number	Date	Country code
	318728 P	2010-03-29	US

Inventors
(72)	GRUBER, Harry, E., US JOLLY, Douglas, J., US PEREZ, Omar, US OSTERTAG, Derek, G., US ROBBINS, Joan, M., US

Grantee
(73)	Tocagen Inc., 3030 Bunker Hill Street Suite 230, San Diego, CA 92109, US

Title
(54)	Medical use of a therapeutic combination comprising a thymosin-1-alpha polypeptide and a replication competent retroviral vector for the expression of cytosine deaminase.
	Medical use of a therapeutic combination comprising a thymosin-1-alpha polypeptide and a replication competent retroviral vector for the expression of cytosine deaminase.